(Q44046271)

29 November 2017

title

Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands (English)

1 reference

29 November 2017

0 references

4

1 reference

29 November 2017

9

Tjeerd G Kimman

1 reference

29 November 2017

1

Hein J Boot

1 reference

29 November 2017

3

Hester E de Melker

1 reference

29 November 2017

8

Chris J L M Meijer

1 reference

29 November 2017

Iris Wallenburg

2

1 reference

29 November 2017

Annette A M Gerritsen

series ordinal

5

1 reference

29 November 2017

Nicoline A van der Maas

series ordinal

6

1 reference

29 November 2017

Johannes Berkhof

series ordinal

7

1 reference

29 November 2017

language of work or name

English

0 references

publication date

21 June 2007

1 reference

29 November 2017

1 reference

29 November 2017

volume

25

1 reference

29 November 2017

issue

33

1 reference

29 November 2017

page(s)

6245-6256

1 reference

Systemic immunosuppression by HIV infection influences HPV transcription and thus local immune responses in condyloma acuminatum

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Human papillomavirus type 18 variant lineages in United States populations characterized by sequence analysis of LCR-E6, E2, and L1 regions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Human papillomavirus testing on self-sampled cervicovaginal brushes: an effective alternative to protect nonresponders in cervical screening programs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

The epidemiology of human papillomavirus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Effects of HPV detection in population-based screening programmes for cervical cancer; a Dutch moment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline or mild dyskaryosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Natural history and screening model for high-risk human papillomavirus infection, neoplasia and cervical cancer in the Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Assessing the introduction of universal varicella vaccination in the Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Nonattendance is still the main limitation for the effectiveness of screening for cervical cancer in the Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

The causal relation between human papillomavirus and cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

HPV testing in cervical screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Cervical cancer in the Netherlands 1989-1998: Decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Prevalence of types 16 and 33 is increased in high-risk human papillomavirus positive women with cervical intraepithelial neoplasia grade 2 or worse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Chapter 6: Epidemiology and transmission dynamics of genital HPV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Perinatal infection and persistence of human papillomavirus types 16 and 18 in infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Vaccination against multiple HPV types

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Variations in the age-specific curves of human papillomavirus prevalence in women worldwide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Spontaneously regressing oral papillomas induce systemic antibodies that neutralize canine oral papillomavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Human papillomavirus infection and disease in HIV-infected individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Herpes simplex virus type 2: a possible interaction with human papillomavirus types 16/18 in the development of invasive cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Human papillomavirus vaccines and prevention of cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Vaccination as a prevention strategy for human papillomavirus-related diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Viral load as a determinant for transmission of human papillomavirus type 16 from mother to child

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Developing a vaccination evaluation model to support evidence-based decision making on national immunization programs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Chapter 7: Achievements and limitations of cervical cytology screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

A controlled trial of a human papillomavirus type 16 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Chapter 13: Current findings from prophylactic HPV vaccine trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Human papillomavirus in malignant cervical lesions in Surinam, a high-risk country, compared to the Netherlands, a low-risk country

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Potential health and economic impact of adding a human papillomavirus vaccine to screening programs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Vaccines for cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Heritability of cervical tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: cross sectional questionnaire study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Parental perspectives on vaccinating children against sexually transmitted infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Impact of HPV infection in adolescent populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Genital warts: current and future management options

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Herpes simplex virus and human papillomavirus in a population-based case-control study of cervical intraepithelial neoplasia grade II-III.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Parental acceptance of the human papillomavirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Chapter 16: HPV vaccines in immunocompromised women and men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Chapter 2: The burden of HPV-related cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Cervical Coinfection with Human Papillomavirus (HPV) Types as a Predictor of Acquisition and Persistence of HPV Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Cost-effectiveness of a potential vaccine for human papillomavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Chapter 25: Education, training, and communication for HPV vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Serological evidence for protection by human papillomavirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Condoms and sexually-transmitted infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Evaluating human papillomavirus vaccination programs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Disability weights for comorbidity and their influence on health-adjusted life expectancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Condom use and the risk of genital human papillomavirus infection in young women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Chapter 14: HPV vaccine introduction in industrialized countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Genomic variation of human papillomavirus type 16 and risk for high grade cervical intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Chapter 24: Psychosocial aspects of vaccine acceptability.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Predictors of STI vaccine acceptability among parents and their adolescent children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

inferred from DOI database lookup

7 January 2021

based on heuristic

Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

inferred from DOI database lookup

7 January 2021

based on heuristic

Characterization of a major neutralizing epitope on human papillomavirus type 16 L1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.061

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2007.05.061

1 reference

29 November 2017

1 reference